Arrowstreet Capital’s Zymeworks ZYME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$18.6M Buy
743,898
+43,896
+6% +$1.04M 0.01% 765
2025
Q4
$18.4M Buy
700,002
+386,249
+123% +$8.42M 0.01% 759
2025
Q3
$5.36M Buy
+313,753
New +$4.49M ﹤0.01% 1151
2024
Q4
Sell
-407,771
Closed -$5.12M 2015
2024
Q3
$5.12M Buy
+407,771
New +$4.44M ﹤0.01% 957
2024
Q2
Sell
-581,558
Closed -$6.12M 1817
2024
Q1
$6.12M Buy
581,558
+214,540
+58% +$2.38M 0.01% 831
2023
Q4
$3.81M Sell
367,018
-104,987
-22% -$837K ﹤0.01% 828
2023
Q3
$2.99M Sell
472,005
-70,225
-13% -$519K ﹤0.01% 766
2023
Q2
$4.68M Buy
+542,230
New +$4.85M 0.01% 640
2021
Q2
Sell
-90,111
Closed -$2.85M 2274
2021
Q1
$2.85M Buy
90,111
+19,598
+28% +$796K ﹤0.01% 1425
2020
Q4
$3.33M Buy
+70,513
New +$3.27M ﹤0.01% 1393
2020
Q1
Sell
-12,264
Closed -$558K 2158
2019
Q4
$558K Buy
+12,264
New +$446K ﹤0.01% 1474
2019
Q2
Sell
-138,896
Closed -$2.25M 1753
2019
Q1
$2.25M Buy
138,896
+102,210
+279% +$1.58M 0.01% 1065
2018
Q4
$539K Buy
36,686
+25,386
+225% +$333K ﹤0.01% 1076
2018
Q3
$177K Buy
+11,300
New +$162K ﹤0.01% 1027

Other funds holding ZYME

Arrowstreet Capital's ZYME Position: Q1 2026 in Review

Arrowstreet Capital increased its Zymeworks (ZYME) stake by 6.3% in Q1 2026, buying an estimated $1.04M and bringing the position to 743,898 shares worth $18.6M. The position accounts for 0.01% of the portfolio, ranked #765.

Arrowstreet Capital first reported a position in ZYME in Q3 2018 and has held it in 14 quarters since. 211 funds tracked by Wall St. Rank hold ZYME as of Q1 2026.

  • Arrowstreet Capital held 743,898 shares of Zymeworks worth $18.6M as of Q1 2026.
  • Arrowstreet Capital bought 43,896 Zymeworks shares in Q1 2026, an estimated $1.04M.
  • Zymeworks made up 0.01% of Arrowstreet Capital's portfolio in Q1 2026, its #765 holding.
  • Arrowstreet Capital first reported a position in Zymeworks in Q3 2018 and has held it in 14 quarters since.
  • 211 funds tracked by Wall St. Rank held Zymeworks as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.